Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOD-101
- Development stage
- Unknown
- Lead developer
- OPKO Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
MOD-101 is a long-acting recombinant fusion protein that was developed by OPKO Biologics (formerly Prolor Biotech) for the treatment of autoimmune diseases. It was designed as a long-acting version of etanercept, utilizing proprietary Carboxyl Terminal Peptide (CTP) technology to extend the protein's half-life and reduce injection frequency. The molecule consists of the extracellular portion of the human tumor necrosis factor receptor (TNFR) fused to the Fc portion of human IgG1. By acting as a decoy receptor, MOD-101 binds to and neutralizes tumor necrosis factor-alpha (TNF-alpha), preventing it from triggering inflammatory pathways. The development of MOD-101 was discontinued by the company around 2010-2011.
- Other names
- TNFR-Fc-CTPlong-acting etanercept
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on MOD-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOD-101.